Dongyao Pharmaceutical-B (01875) announced that as of September 30, 2024, during the nine-month period, the group's revenue...
According to the Zhitong Finance APP, Dongyao Pharmaceutical-B (01875) announced that as of September 30, 2024, during the nine-month period, the group's revenue increased by 49% year-on-year to 0.809 billion yuan, mainly due to the steady growth of self-developed product sales and CDMO/CMO business. The net income reached 35.403 million yuan.